Most IV HTN Meds Ordered for Patients With SBP <180 mm Hg

This article originally appeared here.
Share this content:
Most IV HTN Meds Ordered for Patients With SBP &#60;180 mm Hg
Most IV HTN Meds Ordered for Patients With SBP <180 mm Hg

THURSDAY, Nov. 19, 2015 (HealthDay News) -- Intravenous (IV) antihypertensives are often ordered and administered for patients with asymptomatic uncontrolled blood pressure (BP) levels that are not associated with immediate cardiovascular risk, according to a study published online Nov. 12 in the Journal of Hospital Medicine.

Melissa Lipari, Pharm.D., from Wayne State University in Detroit, and colleagues examined the frequency of prescribing and administering episodic IV antihypertensives and outcome in non-critically ill, hospitalized patients. Data were included for 246 patients with an episodic IV antihypertensive order.

Of the patients with an episodic IV antihypertensive order, 172 received 458 doses, with 48 percent receiving a single dose. The researchers found that more than 98 and 84.5 percent of episodic IV antihypertensive doses were administrated for systolic blood pressure (SBP) of <200 mm Hg and <180 mm Hg, respectively. For patients receiving IV hydralazine and labetalol, there was a statistically significant decrease in average SBP and diastolic BP within six hours of administration. The oral inpatient medication regimen was adjusted in 52 percent of patients after administration of IV antihypertensives; compared to patients with no change to their oral regimens, these patients had a greater SBP reduction from admission to discharge.

"IV antihypertensive drugs are ordered and administered in patients with asymptomatic, uncontrolled BP for levels unassociated with substantive immediate cardiovascular risk, which may cause adverse effects," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »